***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: PURPOSE This trial was conducted to evaluate the effects of oligofructose-enriched inulin on some of cardiovascular disease risk factors in women with type 2 diabetes . METHODS 52 females ( 25 < BMI < 35 kg/m2 ) with type 2 diabetes were r and omly assigned to two groups . Participants received 10g/d oligofructose-enriched inulin ( n=27 ) or 10g/d placebo ( n=25 ) for 8 weeks . Fasting blood sample s were taken to measure metabolic profiles , malondialdehyd and antioxidant enzymes at baseline and after the 8 weeks intervention . Paired , unpaired sample t-test and analysis of covariance were used to comparison of quantitative variables . RESULTS After 8 weeks , in the oligofructose-enriched inulin group there was a significant increase in total antioxidant capacity ( 0.2 mmol/l , 20.0 % ) and a significant decrease in fasting plasma glucose ( 19.2 mg/dL , 9.4 % ) HbA1c ( 0.5 % , 8.4 % ) , total cholesterol ( TC ) ( 28.0 mg/dL , 14.1 % ) , low-density lipoprotein cholesterol ( LDL-c ) ( 22.0 mg/dL , 21.7 % ) , TC/HDL-c ratio ( 0.73 , 20.7 % ) , LDL-c/HDL-c ratio ( 0.55 , 27.5 % ) and malondialdehyd ( 1.7 nmol/ml , 39.7 % ) compared to the placebo group . Changes in concentrations of triglycerides , high-density lipoprotein cholesterol ( HDLc ) , superoxide dismutase , catalase and glutathione peroxidase were not significant in oligofructose-enriched inulin group compared to the placebo group . CONCLUSION Oligofructose-enriched inulin may improve glycemic indices , lipid profile , antioxidant status and malondialdehyd in women with type 2 diabetes Abstract To evaluate the effects of the new resistant starch ( RS ) formula , PPB-R-203 , on glucose homeostasis in healthy subjects and subjects with type 2 diabetes . A cohort consisting of 40 healthy participants received test and control diets and was checked for up to 3 hours post-meal . A r and omized , 2-regimen , cross-over , comparative study was conducted in 44 subjects with type 2 diabetes and glycemic control was assessed with a continuous glucose monitoring system . In healthy participants , serum glucose values and incremental areas under the glucose curves ( AUC ) were significantly lower in the PPB-R-203 than the control group ( P < 0.05 ) . In patients with type 2 diabetes  , mean blood glucose concentrations for subjects on the control regimen were higher than those for subjects on the PPB-R-203-based regimen ( 7.9 ± 1.7 , 95 % confidence interval [ CI ] 7.4–8.4 vs 7.4 ± 1.6 , 95 % CI 6.9–7.9 mmol/L , respectively ; P = 0.023 ) . AUCs for total blood glucose and hyperglycemia ( glucose > 10 mmol/L ) were also reduced for subjects on the PPB-R-203-based regimen as compared with those on control regimen ( total blood glucose : 16.2 ± 4.0 , 95 % CI 14.9–17.4 vs 18.7 ± 4.0 , 95 % CI 17.6–20.1 , P < 0.001 ; hyperglycemia : 4.9 ± 5.7 , 95 % CI 3.1–6.6 vs 6.3 ± 6.4 , 95 % CI 4.3–8.3 mmol/L × day , P = 0.021 ) . However , AUC measurements for hypoglycemia ( glucose < 3.9 mmol/l ) were not statistically significant . A PPB-R-203-based diet reduced postpr and ial hyperglycemia in patients with type 2 diabetes without increasing the risk of hypoglycemia or glucose excursion Resistant starch ( RS ) has been shown to beneficially affect insulin sensitivity in healthy individuals and those with metabolic syndrome , but its effects on human type 2 diabetes ( T2DM ) are unknown . This study aim ed to determine the effects of increased RS consumption on insulin sensitivity and glucose control and changes in postpr and ial metabolites and body fat in T2DM . Seventeen individuals with well-controlled T2DM ( HbA1c 46.6±2 mmol/mol ) consumed , in a r and om order , either 40 g of type 2 RS ( HAM-RS2 ) or a placebo  , daily for 12 weeks with a 12-week washout period in between . At the end of each intervention period , participants attended for three metabolic investigations : a two-step euglycemic – hyperinsulinemic clamp combined with an infusion of [ 6,6 - 2H2 ] glucose , a meal tolerance test ( MTT ) with arterio-venous sampling across the forearm , and whole-body imaging . HAM-RS2 result ed in significantly lower postpr and ial glucose concentrations ( P=0.045 ) and a trend for greater glucose uptake across the forearm muscle ( P=0.077 ) ; however , there was no effect of HAM-RS2 on hepatic or peripheral insulin sensitivity , or on HbA1c . Fasting non-esterified fatty acid ( NEFA ) concentrations were significantly lower ( P=0.004 ) and NEFA suppression was greater during the clamp with HAM-RS2 ( P=0.001 ) . Fasting triglyceride ( TG ) concentrations and soleus intramuscular TG concentrations were significantly higher following the consumption of HAM-RS2 ( P=0.039 and P=0.027 respectively ) . Although fasting GLP1 concentrations were significantly lower following HAM-RS2 consumption ( P=0.049 ) , postpr and ial GLP1 excursions during the MTT were significantly greater ( P=0.009 ) . HAM-RS2 did not improve tissue insulin sensitivity in well-controlled T2DM , but demonstrated beneficial effects on meal h and ling , possibly due to higher postpr and ial GLP1 BACKGROUND Fructooligosaccharides have been cl aim ed to lower fasting glycemia and serum total cholesterol concentrations , possibly via effects of short-chain fatty acids produced during fermentation . OBJECTIVE We studied the effects of fructooligosaccharides on blood glucose , serum lipids , and serum acetate in 20 patients with type 2 diabetes . DESIGN In a r and omized , single-blind , crossover design , patients consumed either glucose as a placebo ( 4 g/d ) or fructooligosaccharides ( 15 g/d ) for 20 d each . Average daily intakes of energy , macronutrients , and dietary fiber were similar with both treatments . RESULTS Compliance , expressed as the proportion of supplements not returned , was near 100 % during both treatments . Fructooligosaccharides did not significantly affect fasting concentrations ( mmol/L ) of serum total cholesterol ( 95 % CI : -0.07 , 0.48 ) , HDL cholesterol ( -0.04 , 0.04 ) , LDL cholesterol ( -0.06 , 0.34 ) , serum triacylglycerols ( -0.21 , 0.44 ) , serum free fatty acids ( -0.08 , 0.04 ) , serum acetate ( -0.01 , 0.01 ) , or blood glucose ( -0.37 , 0.40 ) . CONCLUSIONS We conclude that 20 d of dietary supplementation with fructooligosaccharides had no major effect on blood glucose , serum lipids , or serum acetate in patients with type 2 diabetes . This lack of effect was not due to changes in dietary intake , insufficient statistical power , or noncompliance of the patients Short-chain fructooligosaccharides ( FOS ) are prebiotics , which escape digestion in the small intestine and are fermented by the colonic microflora into short-chain fatty acids . Recently , we found that the daily consumption of 20 g FOS decreased basal hepatic glucose production in healthy subjects without any effect on insulin-stimulated glucose metabolism . In this study , we evaluated the effects of the chronic ingestion of FOS on plasma lipid and glucose concentrations , hepatic glucose production and insulin resistance in type 2 diabetics . Type 2 diabetic volunteers ( n = 10 ; 6 men , 4 women ) received either 20 g/d FOS or sucrose for 4 wk in a double-blind crossover design . FOS did not modify fasting plasma glucose and insulin concentrations or basal hepatic glucose production . The plasma glucose response to a fixed exogenous insulin bolus did not differ at the end of the two periods . Erythrocyte insulin binding also did not differ . Serum triacylglycerol , total and HDL cholesterol , free fatty acid , apolipoproteins A1 and B and lipoprotein ( a ) concentrations were not modified by the chronic ingestion of FOS . We conclude that 4 wk of 20 g/d of FOS had no effect on glucose and lipid metabolism in type 2 diabetics Improvement of insulin resistance and inflammation is a basic strategy in the management of type 2 diabetes . There is limited evidence that prebiotics improve insulin resistance and inflammation . However , the ameliorating effect of resistant dextrin , as a prebiotic , on insulin resistance and inflammation in patients with type 2 diabetes has not been investigated so far . Therefore , the present study aim ed to examine the effects of resistant dextrin on insulin resistance and inflammation in type 2 diabetic patients . In a r and omised controlled clinical trial , fifty-five women with type 2 diabetes were assigned to two groups : the intervention group ( n 30 ) and the control group ( n 25 ) . The intervention group received a daily supplement of 10 g resistant dextrin and the control group received a similar amount of maltodextrin as placebo for 8 weeks . Fasting plasma glucose ( FPG ) , HbA1c , insulin , high-sensitivity C-reactive protein ( hs-CRP ) , IL-6 , TNF-α , malondialdehyde ( MDA ) and serum endotoxin concentrations were measured before and after the intervention . Data were analysed using SPSS ( version 13 ) . Paired and unpaired t tests and ANCOVA were used to compare quantitative variables after the intervention . Patients supplemented with resistant dextrin exhibited a significant decrease in fasting insulin ( 20.1 pmol/l , 22.8 % ) , homeostasis model assessment of insulin resistance ( 1.3 , 24.9 % ) , quantitative insulin sensitivity check index ( 0.2 , 7.2 % ) , IL-6 ( 1.4 pg/ml , 28.4 % ) , TNF-α ( 5.4 pg/ml , 18.8 % ) , MDA ( 1.2 nmol/ml , 25.6 % ) and endotoxin ( 6.2 endotoxin units/ml , 17.8 % ) concentrations than those supplemented with maltodextrin ( P < 0.05 ) . Decreases in FPG ( 0.05 mmol/l , 0.6 % ) , HbA1c ( 0.5 % , 9.6 % ) and hs-CRP ( 2.7 ng/ml , 35.1 % ) concentrations in the resistant dextrin group were not significant when compared with the maltodextrin group . In conclusion , resistant dextrin supplementation can modulate inflammation and improve insulin resistance in women with type 2 diabetes AIM Previous studies have shown that the water-soluble dietary fibre betaglucan , a natural component of oats , reduces cholesterol and postpr and ial hyperglycaemia . The aim of the present study was to investigate the effect of betaglucan-enriched bread consumption on the lipid profile and glucose homoeostasis of patients with type 2 diabetes ( T2D ) . METHODS We conducted a r and omized , double-blind study in which 46 patients with T2D and LDL-C greater than 3.37 mmol/l ( 130 mg/dl ) were r and omized to incorporate into their diet , for 3 weeks , either bread enriched with betaglucan ( providing 3g/day of betaglucan ) or white bread without betaglucan . RESULTS The consumption of bread containing betaglucan led to significant reductions ( vs the control group ) in LDL-C of 0.66 mmol/l ( 15.79 % ) versus 0.11 mmol/l ( 2.71 % ) ( P=0.009 ) , in 
    Output:
    
Benefits from resistant starch , resistant dextrin , and oligofructose-enriched inulin were most frequent .
Based on these results , there is fair evidence that prebiotics and substances with prebiotic properties may improve metabolic and inflammatory biomarkers related to T2DM in women aged 18 years at least .
Interventions with resistant starch , resistant dextrin , and oligofructose-enriched inulin exhibited the strongest evidence for improvements due to the quantity of publications and quality grade s. Other prebiotics and substances with prebiotic properties show promise but the number of studies is few .